Tag
Hikal Limited
5 articles
Hikal Limited’s strong Q2 FY27 results, marked by a 36% year-over-year revenue increase to ₹434 crore, highlight the company’s momentum in both pharmaceuticals and crop protection segments. New business wins, including a multi-year CDMO contract with a European agrochemical company, and successful regulatory inspections by Swissmedic and others, underscore Hikal's growing technical capabilities and expanding market access. Management’s reiteration of full-year guidance suggests continued confidence in achieving mid-teen revenue growth and improved profitability, positioning the company to capitalize on increasing demand for its contract development and manufacturing services amid ongoing geopolitical diversification efforts.
Hikal Q2 FY27 Revenue INR434 Crores, EBITDA INR45 Crores
Hikal reported Q2 FY27 revenue of INR434 crores with EBITDA of INR45 crores and margin of 10.3%, while H1 FY27 revenue stood at INR837 crores with EBITDA of INR82 crores.
The company signed a multi-ye
Kalyani Investment Q2 Net Profit Up 17% YoY
Kalyani Investment reported Q2 FY26 standalone net profit of ₹363.12 million, up 17% YoY, with dividend income of ₹440.47 million.
Total comprehensive income showed a loss of ₹12,005.57 million due to
Hikal Q2 FY27 Earnings Conference Call Recording
Hikal Ltd. disclosed availability of its Q2 & H1 FY27 earnings conference call audio recording on its website.
The call was held on November 3, 2026, at 5:00 PM IST, as per SEBI Listing Regulations.
T
Hikal Authorizes KMP for Materiality Determination
Hikal Limited's Board authorizes three Key Managerial Personnel to determine materiality and make stock exchange disclosures.
Chairman Mr. Sameer Hiremath is authorized for materiality determination a
Hikal Bengaluru API Facility Swissmedic GMP Certified
Hikal Limited's Bengaluru API manufacturing facility received GMP certification from Swissmedic, the Swiss Agency for Therapeutic Products.
The certification enables expanded market access to European